Sanofi announces closing of Regeneron stock sale
29 Mayo 2020 - 3:01PM
Sanofi announces closing of Regeneron stock sale
Sanofi announces closing of Regeneron stock
sale
PARIS - May 29, 2020 – Sanofi
today announced the closing of its sale of 13.0 million shares of
Regeneron (NASDAQ: REGN) common stock through a registered offering
at a public offering price of $515.00 per share. This includes the
previously announced overallotment option that has been fully
exercised by underwriters. In addition, Sanofi announced the
completion of Regeneron's repurchase of 9.8 million shares or
approximately $5 billion in common stock directly from Sanofi.
As a result of the offering, Sanofi has sold its
entire equity investment in Regeneron, (excluding 400,000 Regeneron
shares, which Sanofi is retaining) for total gross proceeds
amounting to $11.7 billion.
The registered offering and share repurchase
will have no impact on the ongoing collaboration between Sanofi and
Regeneron. The Companies have had a successful and
long-standing clinical and commercial collaboration dating back to
2003 that has resulted in five approved treatments to date with
additional candidates currently in clinical development.
The registered offering was executed
simultaneously in the United States and internationally through
underwriters led by BofA Securities and Goldman Sachs & Co.
LLC, together with Barclays, BNP PARIBAS, Citigroup, J.P. Morgan,
Morgan Stanley as joint book-running managers.
The shares offered to the public are offered
pursuant to an existing effective shelf registration statement
(including a base prospectus) that has been filed by Regeneron with
the U.S. Securities and Exchange Commission (the "SEC"). A
prospectus supplement relating to and describing the terms of the
offering has been filed by Regeneron with the SEC and is available
on the SEC website at www.sec.gov. Alternatively, any
underwriter or any dealer participating in the offering will
arrange to send you the prospectus and the prospectus supplement if
you request them by contacting: (1) BofA Securities, NC1-004-03-43,
200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
Attention: Prospectus Department or by email at
dg.prospectus_requests@bofa.com, or (2) Goldman Sachs & Co.
LLC, Attention: Prospectus Department, 200 West Street, New York,
New York 10282, via telephone: 1-866-471-2526, or via email:
prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy the securities
described herein, nor shall there be any offer or sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
Sanofi
Media Relations Ashleigh KossTel: +1 (908)
981-8745Ashleigh.Koss@Sanofi.com |
Sanofi Investor Relations
Felix Lauscher Tel.: +33 (0)1 53 77 45 45 ir@Sanofi.com |
|
|
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole and the
risks and uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed public offering. Any material effect of COVID-19 on any of
the foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2019. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements. The proposed public offering may not be
successful, and even if it is, we may not achieve the anticipated
benefits thereof. For more information regarding risks and
uncertainties relating to Regeneron, you should review the risks
described in the prospectus supplement and the accompanying
prospectus relating to the offering and those incorporated by
reference therein, including those risks described in Regeneron’s
Annual Report on Form 10-K for the year ended December 31, 2019,
Regeneron’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2020 and in subsequent reports and registration
statements filed from time to time with the SEC. |
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De May 2023 a May 2024